Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2016 2017 2018 2019 (e) 2020 (e) 2021 (e)
Sales 4 860 5 872 6 711 7 654 8 190 8 650
EBITDA 1 435 2 732 3 110 3 355 3 754 3 832
Operating profit (EBIT) 1 331 2 080 2 534 2 261 2 907 2 832
Pre-Tax Profit (EBT) 1 330 2 079 2 554 2 211 2 957 2 892
Net income 896 1 199 2 444 1 953 2 458 2 511
P/E ratio 47,7x 36,4x 17,5x 17,5x 14,4x 14,4x
EPS ( $ ) 7,70 10,3 21,3 17,1 20,8 20,8
Dividend per Share ( $ ) - - - - - -
Yield - - - - - -
Reference price ( $ ) 367,090 375,960 373,500 300,190 300,190 300,190
Announcement Date 02/09/2017
11:30am
02/08/2018
11:30am
02/06/2019
11:30am
- - -
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 2016 2017 2018 2019 (e) 2020 (e) 2021 (e)
Debt - - - - - -
Finance 56,4 706 2 101 5 857 7 594 10 406
Operating income (EBITDA) 1 435 2 732 3 110 3 355 3 754 3 832
Leverage
(Debt/EBITDA)
- - - - - -
Capital Expenditure 512 273 383 418 439 443
Free Cash Flow (FCF) 961 1 034 1 812 2 386 2 534 2 743
Book Value Per Share (BVPS) ( $ ) 42,5 57,1 76,3 110 139 168
Cash Flow per Share ( $ ) 12,7 11,3 19,1 25,9 27,0 24,3
Announcement Date 02/09/2017
11:30am
02/08/2018
11:30am
02/06/2019
11:30am
- - -
Balance Sheet Analysis
Assessed data source
© 2019 S&P Global Market Intelligence
Financial Ratios

Size 2019e 2020e
Capitalization 32 847 M $ -
Entreprise Value (EV) 26 990 M $ 25 254 M $
Valuation 2019e 2020e
P/E ratio (Price / EPS) 17,5x 14,4x
Capitalization / Revenue 4,29x 4,01x
EV / Revenue 3,53x 3,30x
EV / EBITDA 8,04x 7,19x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 2,73x 2,16x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) 29,5% 35,5%
Operating Leverage (Delta EBIT / Delta Sales) - 4,08x
Net Margin (Net Profit / Revenue) 25,5% 30,0%
ROA (Net Profit / Asset) 17,9% 17,2%
ROE (Net Profit / Equities) 23,5% 21,8%
Rate of Dividend - -
Balance Sheet Analysis 2019e 2020e
CAPEX / Sales   5,46% 5,36%
Cash Flow / Sales 37,0% 36,1%
Capital Intensity (Assets / Sales) 1,42x 1,75x
Financial Leverage (Net Debt / EBITDA) - -
EPS & Dividend